Page 32 - Read Online

Page 8 of 9 Sukowati et al. Hepatoma Res 2019;5:2 I http://dx.doi.org/10.20517/2394-5079.2018.106

cancer stem cells? Cancer Res 2011;71:3701-8.
26. Li CH, Wang YJ, Dong W, Xiang S, Liang HF, et al. Hepatic oval cell lines generate hepatocellular carcinoma following transfection
with HBx gene and treatment with aflatoxin B1 in vivo. Cancer Lett 2011;311:1-10.
27. Ng KY, Chai S, Tong M, Guan XY, Lin CH, et al. C-terminal truncated hepatitis B virus X protein promotes hepatocellular
carcinogenesis through induction of cancer and stem cell-like properties. Oncotarget 2016;7:24005-17.
28. Ching RHH, Sze KMF, Lau EYT, Chiu YT, Lee JMF, et al. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity,
self-renewal and drug resistance via STAT3/Nanog signaling pathway. Oncotarget 2017;8:23507-16.
29. Fan H, Zhang H, Pascuzzi PE, Andrisani O. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation
directed by RelA in complex with EZH2 and TET2. Oncogene 2015;35:715-26
30. Zhang X, Liu S, Shen C, Wu Y, Zhang L, et al. DNA methylation consistency implicates the primary tumor cell origin of recurrent
hepatocellular carcinoma. Epigenomics 2015;7:581-92.
31. Hamamoto H, Maemura K, Matsuo K, Taniguchi K, Tanaka Y, et al. Delta-like 3 is silenced by HBx via histone acetylation in HBV-
associated HCCs. Sci Rep 2018;8:4842.
32. Liu J, Jiang J, Mo J, Liu D, Cao D, et al. Global DNA 5-hydroxymethylcytosine and 5-formylcytosine contents are decreased in the
early stage of hepatocellular carcinoma. Hepatology 2018; doi:10.1002/hep.30146.
33. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer
Biol 2014;26:78-88.
34. Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, et al. Significance of hepatitis virus infection in the oncogenic initiation
of hepatocellular carcinoma. World J Gastroenterol 2016;22:1497-512.
35. Kwon YC, Bose SK, Steele R, Meyer K, Di Bisceglie AM, et al. Promotion of cancer stem-like cell properties in hepatitis C virus-
infected hepatocytes. J Virol 2015;89:11549-56.
36. Ali N, Allam H, May R, Sureban SM, Bronze MS, et al. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and
murine tumor xenografts. J Virol 2011;85:12292-303.
37. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009;51:810-20.
38. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV
in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A 2009;106:1548-53.
39. Uthaya Kumar DB, Chen CL, Liu JC, Feldman DE, Sher LS, et al. TLR4 signaling via NANOG cooperates with STAT3 to activate
Twist1 and promote formation of tumor-initiating stem-like cells in livers of mice. Gastroenterology 2016;150:707-19.
40. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, et al. Hepatitis C virus core protein upregulates transforming growth factor-beta
1 transcription. J Med Virol 2004;72:52-9.
41. Sasaki R, Devhare P, Ray RB, Ray R. Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a
xenograft tumor model. Hepatology 2017;66:1766-78.
42. Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, et al. Cancer stem cells generated by alcohol, diabetes, and hepatitis C
virus. J Gastroenterol Hepatol 2012;27 Suppl 2:19-22.
43. Debebe A, Medina V, Chen CY, Mahajan IM, Jia C, et al. Wnt/β-catenin activation and macrophage induction during liver cancer
development following steatosis. Oncogene 2017;36:6020-9.
44. Kwon YC, Sasaki R, Meyer K, Ray R. Hepatitis C virus core protein modulates endoglin (CD105) signaling pathway for liver
pathogenesis. J Virol 2017; doi:10.1128/JVI.01235-17.
45. Fan H, Cui Z, Zhang H, Mani SK, Diab A, et al. DNA demethylation induces SALL4 gene re-expression in subgroups of
hepatocellular carcinoma associated with hepatitis B or C virus infection. Oncogene 2017;36:2435-45.
46. Anfuso B, El-Khobar KE, Sukowati CH, Tiribelli C The multiple origin of cancer stem cells in hepatocellular carcinoma. Clin Res
Hepatol Gastroenterol 2015;39 Suppl 1:S92-7.
47. Chen YL, Lin PY, Ming YZ, Huang WC, Chen RF, et al. The effects of the location of cancer stem cell marker CD133 on the
prognosis of hepatocellular carcinoma patients. BMC Cancer 2017;17:474.
48. Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of
hepatocellular carcinoma. Histopathology 2014;64:935-50.
49. Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, et al. Cytoplasmic expression of CD133 is an important risk factor for
overall survival in hepatocellular carcinoma. Oncol Rep 2010;24:537-46.
50. Ma YC, Yang JY, Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a
meta-analysis. Eur J Gastroenterol Hepatol 2013;25:1007-16.
51. Song W, Li H, Tao K, Li R, Song Z, et al. Expression and clinical significance of the stem cell marker CD133 in hepatocellular
carcinoma. Int J Clin Pract 2008;62:1212-8.
52. Sukowati CHC, Anfuso B, Torre G, Francalanci P, Crocè LS, et al. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in
vivo and in vitro study. PLoS One 2013;8:e76830.
53. Liu R, Shen Y, Nan K, Mi B, Wu T, et al. Association between expression of cancer stem cell markers and poor differentiation of
hepatocellular carcinoma: a meta-analysis (PRISMA). Medicine (Baltimore) 2015;94:e1306.
54. Lingala S, Cui YY, Chen X, Ruebner BH, Qian XF, et al. Immunohistochemical staining of cancer stem cell markers in hepatocellular
carcinoma. Exp Mol Pathol 2010;89:27-35.
55. Dai XM, Yang SL, Zheng XM, Chen GG, Chen J, et al. CD133 expression and α-fetoprotein levels define novel prognostic subtypes
of HBV-associated hepatocellular carcinoma: a long-term follow-up analysis. Oncol Lett 2018;15:2985-91.
56. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus
infection. BMC Cancer 2009;9:324.
57. Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, et al. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated
with HBV infection and poor prognosis. Acta Histochem 2011;113:833-8.